1649 related articles for article (PubMed ID: 31848460)
1. Engineering strategies to overcome the current roadblocks in CAR T cell therapy.
Rafiq S; Hackett CS; Brentjens RJ
Nat Rev Clin Oncol; 2020 Mar; 17(3):147-167. PubMed ID: 31848460
[TBL] [Abstract][Full Text] [Related]
2. Chimeric Antigen Receptor Structure and Manufacturing of Clinical Grade CAR Engineered Cells using Different Bioreactors.
Syed F; El Fakih R; Alahmari AD; Osman Ali AS; Aljurf M
Hematol Oncol Stem Cell Ther; 2022 Nov; 15(3):137-152. PubMed ID: 36395497
[TBL] [Abstract][Full Text] [Related]
3. Biomaterials for chimeric antigen receptor T cell engineering.
Niu H; Zhao P; Sun W
Acta Biomater; 2023 Aug; 166():1-13. PubMed ID: 37137403
[TBL] [Abstract][Full Text] [Related]
4. The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies.
Daei Sorkhabi A; Mohamed Khosroshahi L; Sarkesh A; Mardi A; Aghebati-Maleki A; Aghebati-Maleki L; Baradaran B
Front Immunol; 2023; 14():1113882. PubMed ID: 37020537
[TBL] [Abstract][Full Text] [Related]
5. CAR-T cell therapy: current limitations and potential strategies.
Sterner RC; Sterner RM
Blood Cancer J; 2021 Apr; 11(4):69. PubMed ID: 33824268
[TBL] [Abstract][Full Text] [Related]
6. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
[TBL] [Abstract][Full Text] [Related]
7. Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting.
Sutherland AR; Owens MN; Geyer CR
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33007850
[TBL] [Abstract][Full Text] [Related]
8. Determinants of response and resistance to CAR T cell therapy.
Lesch S; Benmebarek MR; Cadilha BL; Stoiber S; Subklewe M; Endres S; Kobold S
Semin Cancer Biol; 2020 Oct; 65():80-90. PubMed ID: 31705998
[TBL] [Abstract][Full Text] [Related]
9. Strategies to Enhance the Therapeutic Efficacy, Applicability, and Safety of Genetically Engineered Immune Cells.
de Lima SCG; Fantacini DMC; Batista LC; Silveira RM; Furtado IP; Rossetti R; Brand H; Covas DT; de Souza LEB
Crit Rev Immunol; 2021; 41(1):41-67. PubMed ID: 33822524
[TBL] [Abstract][Full Text] [Related]
10. CAR T-cell Therapy: A New Era in Cancer Immunotherapy.
Miliotou AN; Papadopoulou LC
Curr Pharm Biotechnol; 2018; 19(1):5-18. PubMed ID: 29667553
[TBL] [Abstract][Full Text] [Related]
11. CAR T-cell therapy: Reprogramming patient's immune cell to treat cancer.
Mavi AK; Gaur S; Gaur G; Babita ; Kumar N; Kumar U
Cell Signal; 2023 May; 105():110638. PubMed ID: 36822565
[TBL] [Abstract][Full Text] [Related]
12. Synthetic Biology in Chimeric Antigen Receptor T (CAR T) Cell Engineering.
Zhang C; Zhuang Q; Liu J; Liu X
ACS Synth Biol; 2022 Jan; 11(1):1-15. PubMed ID: 35005887
[TBL] [Abstract][Full Text] [Related]
13. Clinical Investigations of CAR-T Cell Therapy for Solid Tumors.
Chen K; Wang S; Qi D; Ma P; Fang Y; Jiang N; Wu E; Li N
Front Immunol; 2022; 13():896685. PubMed ID: 35924243
[TBL] [Abstract][Full Text] [Related]
14. Genome Editing for Engineering the Next Generation of Advanced Immune Cell Therapies.
de Lima SCG; Fantacini DMC; Furtado IP; Rossetti R; Silveira RM; Covas DT; de Souza LEB
Adv Exp Med Biol; 2023; 1429():85-110. PubMed ID: 37486518
[TBL] [Abstract][Full Text] [Related]
15. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor T-cell therapy beyond cancer: current practice and future prospects.
Zhang PF; Xie D; Li Q
Immunotherapy; 2020 Sep; 12(13):1021-1034. PubMed ID: 32727249
[TBL] [Abstract][Full Text] [Related]
17. Management of CAR T-cell Related Toxicities: What did the Learning Curve Teach us so Far?
Murthy HS; Yassine F; Iqbal M; Alotaibi S; Moustafa MA; Kharfan-Dabaja MA
Hematol Oncol Stem Cell Ther; 2022 Nov; 15(3):100-111. PubMed ID: 36395496
[TBL] [Abstract][Full Text] [Related]
18. CAR T-cell therapy: Full speed ahead.
Sermer D; Brentjens R
Hematol Oncol; 2019 Jun; 37 Suppl 1():95-100. PubMed ID: 31187533
[TBL] [Abstract][Full Text] [Related]
19. Overcoming Challenges in Process Development of Cellular Therapies.
Highfill SL; Stroncek DF
Curr Hematol Malig Rep; 2019 Aug; 14(4):269-277. PubMed ID: 31278568
[TBL] [Abstract][Full Text] [Related]
20. CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies.
To V; Evtimov VJ; Jenkin G; Pupovac A; Trounson AO; Boyd RL
Front Immunol; 2022; 13():968395. PubMed ID: 36059451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
